Business Context and Reporting Period
Company: DNA X, Inc. (Ticker: SONM)
Filing Type: Form 8-K (Current Report)
Date of Report: May 20, 2026 (Events reported through May 26, 2026)
Context: The filing discloses the entry into a material definitive agreement involving the issuance of a convertible promissory note and a critical notice regarding potential delisting from The Nasdaq Capital Market due to non-compliance with stockholders' equity requirements.
Key Financial Metrics and Capital Structure
- Debt Issuance: The Company issued a convertible promissory note with a principal amount of $3,052,787.68.
- Transaction Consideration: The aggregate purchase price consisted of $1,800,000 in cash and the surrender of a prior convertible note (principal of $1,200,000 plus $52,787.68 accrued interest).
- Interest Rate: The new note accrues interest at 10% per annum.
- Maturity Date: December 31, 2026.
- Conversion Terms: Convertible into common stock at an initial price of $6.00 per share, subject to stockholder approval and specific adjustment mechanisms (e.g., 80% of closing price during an Event of Default).
- Collateral: The note is secured by a first-priority lien on the Company's membership interests in its wholly-owned subsidiary, DNA X, LLC.
- Stockholders' Equity: As of March 31, 2026, the Company reported a stockholders' deficit of $983,000.
Material Changes and Listing Status
The Company is facing a significant risk of delisting from The Nasdaq Capital Market.
- Non-Compliance: The Company failed to meet Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. Despite a previous determination of regained compliance in February 2026, the March 31, 2026, 10-Q filing revealed a deficit, resulting in non-compliance.
- Delisting Determination: On May 22, 2026, Nasdaq issued a delisting determination letter. Trading is scheduled to be suspended on June 2, 2026, unless an appeal is filed.
- Appeal Status: The Company intends to request a hearing before a Nasdaq Hearing Panel by May 29, 2026. This request is expected to stay the suspension of trading pending the hearing's conclusion.
- Agreement Amendment: Concurrent with the new note issuance, the Company terminated a "Put Option" previously held by the purchaser under a Membership Interest Purchase Agreement.
Guidance, Risks, and Management Commentary
- Use of Proceeds: Proceeds from the new note are restricted to working capital purposes. They cannot be used to satisfy existing debt (except trade payables), redeem stock, or settle litigation.
- Delisting Risks: Management warns that if delisted, the Company may face reduced liquidity, difficulty in obtaining accurate stock quotations, a material decline in stock price, and impaired ability to raise capital. Delisting could also trigger defaults under other agreements.
- Forward-Looking Statements: There is no assurance that the Company will regain compliance with Nasdaq rules or that the Hearing Panel will grant a suspension of delisting.
- Regulatory Compliance: The note issuance relied on exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, sold to an accredited investor.
Investor Verification Checklist
- Verify the status of the Nasdaq Hearing Panel request and the expected timeline for the decision.
- Confirm whether the Company has obtained the necessary stockholder approval required to convert the new note into common stock.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Note (Exhibit 10.2) for specific default triggers and conversion price adjustment formulas.
- Monitor subsequent filings for updates on the Company's stockholders' equity position to assess the likelihood of regaining Nasdaq compliance.
- Check for any cross-default clauses in other outstanding agreements that could be triggered by a potential delisting.